• Skip to main content

DistilGovHealth

DistilNFO GovHealth Advisory

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

A Look at Recent Proposals to Control Drug Spending by Medicare and its Beneficiaries

Share:

August 7, 2019

The affordability of prescription drugs is a pressing concern for many Americans, with broad agreement across the political spectrum that lowering prescription drug costs should be a top priority for Congress. The Trump Administration, members of Congress, and several 2020 presidential candidates have offered proposals to lower drug prices. Many of these proposals would affect prescription drug spending under Medicare, which accounts for 30 percent of national retail spending on drugs and nearly $1 out of every $5 in total Medicare spending (Figure 1).

Figure 1: Spending by Medicare accounts for 30% of total retail prescription drug spending in the U.S.

Prescription drugs are an important component of health care for Medicare beneficiaries, which includes more than 60 million older adults and people with long-term disabilities. The majority of Medicare prescription drug spending is for drugs covered under Part D, the outpatient prescription drug benefit. Medicare Part B also covers drugs that are administered to patients in physician offices and other outpatient settings.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

This brief describes proposed and recent changes to control Medicare drug spending and lower beneficiaries’ out-of-pocket drug costs. We include proposals from the Trump Administration and legislation introduced during the 116th Congress, including legislation that recently passed out of the Senate Finance Committee. We review the implications of these changes for various stakeholders and explain their estimated effects on Medicare and beneficiary spending, to the extent such effects are known, based primarily on estimates from the Congressional Budget Office (CBO).

The brief focuses on drug pricing proposals related to Medicare specifically, rather than broader proposals that are not solely focused on Medicare, including those related to drug importation, generic drug availability, patents, and price transparency.1 While we have made every effort to include the most recent proposals pertaining to Medicare drug costs, policy discussions are evolving rapidly. This brief will be updated as necessary in the future.

 

Date: August 7, 2019

Source: KFF

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Senate’s drug price hearing: 6 takeawaysSenate’s drug price hearing: 6 takeaways
  • 10 Consumer Trends That Will Spark Innovation in 202010 Consumer Trends That Will Spark Innovation in 2020
  • North Dakota Bill Would Set New Terms for TelemedicineNorth Dakota Bill Would Set New Terms for Telemedicine
  • Removing Blockers: Meaningful Steps Forward for Consumer Health Data ControlRemoving Blockers: Meaningful Steps Forward for Consumer Health Data Control
  • Apple’s Healthcare RoadmapApple’s Healthcare Roadmap
  • Senate HELP Passes Health Pricing Bill, May Ease HIPAA EnforcementSenate HELP Passes Health Pricing Bill, May Ease HIPAA Enforcement

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications